Quick Answer
NOVARTIS AG reported R&D Expense of $11.20 billion for fiscal year 2025.
NOVARTIS AG R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $11.20B | +11.8% |
| 2024 | $10.02B | -11.9% |
| 2023 | $11.37B | +24.0% |
| 2022 | $9.17B | +6.1% |
| 2021 | $8.64B | -3.8% |
| 2020 | $8.98B | -4.5% |
| 2019 | $9.40B | +10.8% |
| 2018 | $8.49B | +1.2% |
| 2017 | $8.39B | -7.2% |
| 2016 | $9.04B | — |
- NOVARTIS AG showed an increase of +11.8% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, NOVARTIS AG’s r&d expense has grown by 23.9% (from $9.04 billion to $11.20 billion).
- The most recent figure is from NOVARTIS AG’s fiscal year 2025 report (Form 20-F), filed with the SEC on February 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: